Uterine leiomyoma: Available medical treatments and new possible therapeutic options

Md Soriful Islam, Olga Protic, Stefano Raffaele Giannubilo, Paolo Toti, Andrea Luigi Tranquilli, Felice Petraglia, Mario Castellucci, Pasquapina Ciarmela

Research output: Contribution to journalReview articlepeer-review


Context: Uterine leiomyomas (fibroids or myomas) are benign tumors of the uterus and are clinically apparent in up to 25% of reproductive-age women. Heavy or abnormal uterine bleeding, pelvic pain or pressure, infertility, and recurrent pregnancy loss are generally associated with leiomyoma. Although surgical and radiological therapies are frequently used for the management of this tumor, medical therapies are considered the first-line treatment of leiomyoma. Evidence Acquisition and Synthesis: A review was conducted of electronic and print data comprising both original and review articles on pathophysiology and medical treatments of uterine leiomyoma retrieved from the PubMed or Google Scholar database up to June 2012. These resources were integrated with the authors' knowledge of the field. Conclusion: To date, several pathogenetic factors such as genetic factors, epigenetic factors, estrogens, progesterone, growth factors, cytokines, chemokines, and extracellular matrix components have been implicated in leiomyoma development and growth. On the basis of current hypotheses, several medical therapies have been investigated. GnRH agonist has been approved by US Food and Drug Administration for reducing fibroid volume and related symptoms. In addition, the FDA also approved an intrauterine device, levonorgestrel-releasing intrauterine system (Mirena), for additional use to treat heavy menstrual bleeding in intrauterine device users only. Currently, mifepristone, asoprisnil, ulipristal acetate, and epigallocatechin gallate have been shown to be effective for fibroid regression and symptomatic improvement which are all in clinical trial. In addition, some synthetic and natural compounds as well asgrowth factor inhibitors arenow under laboratory investigation, and they could serve as future therapeutic options.

Original languageEnglish (US)
Pages (from-to)921-934
Number of pages14
JournalJournal of Clinical Endocrinology and Metabolism
Issue number3
StatePublished - Mar 2013
Externally publishedYes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical


Dive into the research topics of 'Uterine leiomyoma: Available medical treatments and new possible therapeutic options'. Together they form a unique fingerprint.

Cite this